We evaluated the effects of bisphosphonate (BP) treatment in five patients with hormone-refractory prostate cancer (HRPC), experiencing bone pain from metastases to the bone, and assessed changes in serum prostate specific antigen (PSA) levels, bone pain, and quality of life (QOL). Treatment with incadronate disodium (10 mg) in saline was administered at 2-week intervals for a total of 6 times. Evaluation of the treatment included the incidence of adverse events, QOL, bone pain, pain scale, and blood analyses including tumor markers. BP treatment was generally well tolerated by all five patients. The effects of BP treatment on serum PSA values were evaluated as prominent response (PR), no change (NC) and progressive disease (PD) in one, two and two cases of PD, respectively. During BP treatment, serum type I procollagen values decreased in patients, but there was no large change in serum type I collagen values. Only one patient experienced increased pain; pain was well controlled in the others. The QOL evaluation by Short-Form 36 (SF-36), showed no change in scores during BP treatment except for general health. These results suggested that BP treatment is safe and feasible. It may be effective for the treatment of those HRPC patients with bone pain and may become one of the choices for treatment of HRPC.われわれは, 骨転移による骨痛有するホルモン不応性前立腺癌(HRPC)5例においてビスホスホネート(BP)治療を行い, 血清PSA値, 骨痛と生活の質(QOL)を評価した.インカドロン2ナトリウム(10mg)を2週ごと, 合計6回施行した.治療効果判定を腫瘍マーカー, 副作用, QOL, 骨痛・疼痛スケールと血液検査で行った.BP治療は, 5例すべて問題なく終了した.治療効果における血清PSA値は, 1例PR, 2例NCと2例PDであった.BP治療期間中血清I型プロコラーゲン値は患者で減少した.しかしながら, 血清I型コラーゲン値の大きな変化はみられなかった.1人の患者において疼痛の増加が見られたが, 他の症例では疼痛の悪化を認めなかった.Short-Form 36(SF-36)によるQOL評価では, 全体的健康感以外BP治療の間のスコアは不変であった.これらの結果からBP治療が安全に施行でき, 骨痛を伴ったHRPC患者に効果的である可能性が認められ, HRPCに対する治療の1つの選択肢になることが示唆された(著者抄録
